Logo image of MYGN

MYRIAD GENETICS INC (MYGN) Stock Fundamental Analysis

NASDAQ:MYGN - Nasdaq - US62855J1043 - Common Stock - Currency: USD

4.92  -0.15 (-2.96%)

After market: 4.92 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MYGN. MYGN was compared to 557 industry peers in the Biotechnology industry. MYGN has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, MYGN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year MYGN was profitable.
MYGN had a negative operating cash flow in the past year.
MYGN had negative earnings in each of the past 5 years.
In multiple years MYGN reported negative operating cash flow during the last 5 years.
MYGN Yearly Net Income VS EBIT VS OCF VS FCFMYGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

MYGN's Return On Assets of -12.39% is amongst the best of the industry. MYGN outperforms 82.76% of its industry peers.
With an excellent Return On Equity value of -18.16%, MYGN belongs to the best of the industry, outperforming 86.18% of the companies in the same industry.
Industry RankSector Rank
ROA -12.39%
ROE -18.16%
ROIC N/A
ROA(3y)-14.9%
ROA(5y)-12.19%
ROE(3y)-21.47%
ROE(5y)-17.79%
ROIC(3y)N/A
ROIC(5y)N/A
MYGN Yearly ROA, ROE, ROICMYGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

Looking at the Gross Margin, with a value of 69.89%, MYGN belongs to the top of the industry, outperforming 82.05% of the companies in the same industry.
In the last couple of years the Gross Margin of MYGN has declined.
MYGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
MYGN Yearly Profit, Operating, Gross MarginsMYGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

2

2. Health

2.1 Basic Checks

MYGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
MYGN has more shares outstanding than it did 1 year ago.
MYGN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MYGN is higher compared to a year ago.
MYGN Yearly Shares OutstandingMYGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
MYGN Yearly Total Debt VS Total AssetsMYGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of 0.51, we must say that MYGN is in the distress zone and has some risk of bankruptcy.
MYGN's Altman-Z score of 0.51 is fine compared to the rest of the industry. MYGN outperforms 64.81% of its industry peers.
MYGN has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.06, MYGN is doing worse than 63.20% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 0.51
ROIC/WACCN/A
WACC8.61%
MYGN Yearly LT Debt VS Equity VS FCFMYGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 1.82 indicates that MYGN should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.82, MYGN is doing worse than 78.46% of the companies in the same industry.
A Quick Ratio of 1.65 indicates that MYGN should not have too much problems paying its short term obligations.
MYGN has a Quick ratio of 1.65. This is in the lower half of the industry: MYGN underperforms 79.89% of its industry peers.
Industry RankSector Rank
Current Ratio 1.82
Quick Ratio 1.65
MYGN Yearly Current Assets VS Current LiabilitesMYGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

MYGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 237.50%, which is quite impressive.
MYGN shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 86.63% yearly.
MYGN shows a small growth in Revenue. In the last year, the Revenue has grown by 7.38%.
Measured over the past years, MYGN shows a decrease in Revenue. The Revenue has been decreasing by -0.32% on average per year.
EPS 1Y (TTM)237.5%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)7.38%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%-3.12%

3.2 Future

The Earnings Per Share is expected to grow by 36.32% on average over the next years. This is a very strong growth
Based on estimates for the next years, MYGN will show a small growth in Revenue. The Revenue will grow by 4.75% on average per year.
EPS Next Y-102.8%
EPS Next 2Y12.29%
EPS Next 3Y34.33%
EPS Next 5Y36.32%
Revenue Next Year-3.38%
Revenue Next 2Y1.59%
Revenue Next 3Y3.48%
Revenue Next 5Y4.75%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MYGN Yearly Revenue VS EstimatesMYGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
MYGN Yearly EPS VS EstimatesMYGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 -0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 44.73, MYGN can be considered very expensive at the moment.
92.46% of the companies in the same industry are more expensive than MYGN, based on the Price/Earnings ratio.
MYGN's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.35.
A Price/Forward Earnings ratio of 30.01 indicates a quite expensive valuation of MYGN.
90.48% of the companies in the same industry are more expensive than MYGN, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.19. MYGN is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 44.73
Fwd PE 30.01
MYGN Price Earnings VS Forward Price EarningsMYGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYGN Per share dataMYGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

MYGN's earnings are expected to grow with 34.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.29%
EPS Next 3Y34.33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MYGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MYRIAD GENETICS INC

NASDAQ:MYGN (6/20/2025, 8:00:02 PM)

After market: 4.92 0 (0%)

4.92

-0.15 (-2.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners103.92%
Inst Owner Change1.4%
Ins Owners2.55%
Ins Owner Change14.93%
Market Cap453.53M
Analysts54.55
Price Target7.65 (55.49%)
Short Float %9.8%
Short Ratio3.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)101.18%
Min EPS beat(2)-2.9%
Max EPS beat(2)205.26%
EPS beat(4)3
Avg EPS beat(4)198.46%
Min EPS beat(4)-2.9%
Max EPS beat(4)500.81%
EPS beat(8)6
Avg EPS beat(8)133.36%
EPS beat(12)9
Avg EPS beat(12)102.73%
EPS beat(16)13
Avg EPS beat(16)96.48%
Revenue beat(2)0
Avg Revenue beat(2)-1.6%
Min Revenue beat(2)-2.43%
Max Revenue beat(2)-0.76%
Revenue beat(4)2
Avg Revenue beat(4)0.1%
Min Revenue beat(4)-2.43%
Max Revenue beat(4)2.44%
Revenue beat(8)4
Avg Revenue beat(8)0.5%
Revenue beat(12)7
Avg Revenue beat(12)0.25%
Revenue beat(16)9
Avg Revenue beat(16)1.25%
PT rev (1m)-50.11%
PT rev (3m)-59.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-21.9%
EPS NY rev (1m)0%
EPS NY rev (3m)-106.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.2%
Revenue NY rev (1m)-0.23%
Revenue NY rev (3m)-4.14%
Valuation
Industry RankSector Rank
PE 44.73
Fwd PE 30.01
P/S 0.54
P/FCF N/A
P/OCF N/A
P/B 0.65
P/tB 2.98
EV/EBITDA N/A
EPS(TTM)0.11
EY2.24%
EPS(NY)0.16
Fwd EY3.33%
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS9.09
BVpS7.61
TBVpS1.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.39%
ROE -18.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.89%
FCFM N/A
ROA(3y)-14.9%
ROA(5y)-12.19%
ROE(3y)-21.47%
ROE(5y)-17.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
F-Score5
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.53%
Cap/Sales 3.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.82
Quick Ratio 1.65
Altman-Z 0.51
F-Score5
WACC8.61%
ROIC/WACCN/A
Cap/Depr(3y)84.3%
Cap/Depr(5y)59.15%
Cap/Sales(3y)6.65%
Cap/Sales(5y)4.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)237.5%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y-102.8%
EPS Next 2Y12.29%
EPS Next 3Y34.33%
EPS Next 5Y36.32%
Revenue 1Y (TTM)7.38%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%-3.12%
Revenue Next Year-3.38%
Revenue Next 2Y1.59%
Revenue Next 3Y3.48%
Revenue Next 5Y4.75%
EBIT growth 1Y34.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.77%
EBIT Next 3Y48%
EBIT Next 5Y46.13%
FCF growth 1Y79.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y92.16%
OCF growth 3YN/A
OCF growth 5YN/A